Novel combined vaccine compositions are provided, comprising a hepatitis B viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, a herpes simplex viral antigen, a VZV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.

 
Web www.patentalert.com

< Therapeutic human anti-IL1-R1 monoclonal antibody

> Papilloma virus capsomere vaccine formulations and methods of use

~ 00432